Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.57 |
| ▸ | PRCP | P42785 | 2/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513805 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2MAPTALDH1A1OPRM1PRCP | |
| SCHEMBL643311 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2MAPTALDH1A1OPRM1PRCP | |
| SCHEMBL15421539 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2MAPTALDH1A1OPRM1PRCP | |
| SCHEMBL12312033 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2MAPTALDH1A1OPRM1PRCP | |
| SCHEMBL18586033 | 0.85 | OPRM1 (0.54) | SMN1; SMN2MAPTALDH1A1OPRM1PRCP | |
| SCHEMBL18586549 | 0.85 | OPRM1 (0.54) | SMN1; SMN2MAPTALDH1A1OPRM1PRCP | |
| SCHEMBL14591478 | 0.84 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPTALDH1A1OPRM1PRCP | |
| Hydrochloric Acid SCHEMBL8470875 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPTALDH1A1OPRM1PRCP | |
| SCHEMBL11610319 | 0.84 | HSD17B10 (0.50) | SMN1; SMN2MAPTALDH1A1OPRM1PRCP | |
| SCHEMBL10775754 | 0.82 | OPRM1 (0.65) | SMN1; SMN2MAPTALDH1A1OPRM1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257527-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | claimed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | claimed |
| EP-2257527-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | disclosed |
| CN-100432056-C | Tetrahydroisoquinolinylacetamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-12 | — | — | CN | disclosed |
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-08-10 | — | — | US | disclosed |
| CN-1764647-A | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | SMN1; SMN2 4271/4885MAPT 2015/4885ALDH1A1 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.